Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus
Nonalcoholic fatty liver disease (NAFLD) affects 25% of adults in the general population and is a disease spectrum ranging from steatosis to nonalcoholic steatohepatitis (NASH) to end-stage liver disease. NAFLD is an independent risk factor for cardiovascular disease, diabetes mellitus, and all-caus...
Gespeichert in:
| Veröffentlicht in: | Clinical gastroenterology and hepatology 2022-02, Vol.20 (2), p.256-268 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 268 |
|---|---|
| container_issue | 2 |
| container_start_page | 256 |
| container_title | Clinical gastroenterology and hepatology |
| container_volume | 20 |
| creator | Lake, Jordan E. Overton, Turner Naggie, Susanna Sulkowski, Mark Loomba, Rohit Kleiner, David E. Price, Jennifer C. Chew, Kara W. Chung, Raymond T. Corey, Kathleen E. |
| description | Nonalcoholic fatty liver disease (NAFLD) affects 25% of adults in the general population and is a disease spectrum ranging from steatosis to nonalcoholic steatohepatitis (NASH) to end-stage liver disease. NAFLD is an independent risk factor for cardiovascular disease, diabetes mellitus, and all-cause mortality, and NASH cirrhosis is a frequent indication for liver transplantation. In persons with human immunodeficiency virus (PWH), chronic liver disease is the second leading cause of non–human immunodeficiency virus–related mortality. Between 20% and 63% of PWH have NASH, and 14% to 63% have NASH with fibrosis. However, little is known about the optimal diagnostic strategies, risk factors for, and treatment of NAFLD in PWH. Here, we review current data on and identify knowledge gaps in the epidemiology, pathophysiology, diagnosis, and management of NAFLD in PWH and highlight priorities for research.
[Display omitted] |
| doi_str_mv | 10.1016/j.cgh.2020.10.018 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9069630</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1542356520314312</els_id><sourcerecordid>2452099391</sourcerecordid><originalsourceid>FETCH-LOGICAL-c451t-b0c1313385e2ed2f6e29bfaa07261da1d62ffad514dd4a36b5b9f1778d07c9d83</originalsourceid><addsrcrecordid>eNp9kUtPGzEUha2qqEDoD-gGedlNUj_mZSFVqlIgSFFBiMfS8th3iKMZO7VnAvn3dZqA2g0rX_uee651PoS-UDKhhBbflhP9tJgwwrb3CaHVB3RE84yNy5JmH_c1z4v8EB3HuCSEiUyUn9Ah56QQVcWOkDl_WUHo8Y1y0OJbWFt4xt7hX96pVvuFb63GF6rvN3hu1xDwTxtBRcDW4RsI0buIH22_wLOhUw5fdd3gvIHGagtOb_CDDUM8QQeNaiN83p8jdH9xfjedjefXl1fTH_OxznLaj2uiKaecVzkwMKwpgIm6UYqUrKBGUVOwplEmp5kxmeJFndeioWVZGVJqYSo-Qt93vquh7sBocH1QrVwF26mwkV5Z-X_H2YV88mspUhwFJ8ng694g-N8DxF52Nmpo25SOH6JkWc6IEFzQJKU7qQ4-xgDN2xpK5JaOXMpER27pbJ8SnTRz-u__3iZecSTB2U4AKaWEIsj4N0cwNoDupfH2Hfs_QYyiJw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2452099391</pqid></control><display><type>article</type><title>Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Lake, Jordan E. ; Overton, Turner ; Naggie, Susanna ; Sulkowski, Mark ; Loomba, Rohit ; Kleiner, David E. ; Price, Jennifer C. ; Chew, Kara W. ; Chung, Raymond T. ; Corey, Kathleen E.</creator><creatorcontrib>Lake, Jordan E. ; Overton, Turner ; Naggie, Susanna ; Sulkowski, Mark ; Loomba, Rohit ; Kleiner, David E. ; Price, Jennifer C. ; Chew, Kara W. ; Chung, Raymond T. ; Corey, Kathleen E.</creatorcontrib><description>Nonalcoholic fatty liver disease (NAFLD) affects 25% of adults in the general population and is a disease spectrum ranging from steatosis to nonalcoholic steatohepatitis (NASH) to end-stage liver disease. NAFLD is an independent risk factor for cardiovascular disease, diabetes mellitus, and all-cause mortality, and NASH cirrhosis is a frequent indication for liver transplantation. In persons with human immunodeficiency virus (PWH), chronic liver disease is the second leading cause of non–human immunodeficiency virus–related mortality. Between 20% and 63% of PWH have NASH, and 14% to 63% have NASH with fibrosis. However, little is known about the optimal diagnostic strategies, risk factors for, and treatment of NAFLD in PWH. Here, we review current data on and identify knowledge gaps in the epidemiology, pathophysiology, diagnosis, and management of NAFLD in PWH and highlight priorities for research.
[Display omitted]</description><identifier>ISSN: 1542-3565</identifier><identifier>EISSN: 1542-7714</identifier><identifier>DOI: 10.1016/j.cgh.2020.10.018</identifier><identifier>PMID: 33069882</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Antiretroviral Therapy (ART) ; End Stage Liver Disease - pathology ; HIV ; HIV Infections - complications ; HIV Infections - epidemiology ; HIV Infections - pathology ; Human Immunodeficiency Virus (HIV) ; Humans ; Liver - pathology ; Liver Cirrhosis - epidemiology ; Liver Cirrhosis - pathology ; Liver Cirrhosis - therapy ; Non-alcoholic Fatty Liver Disease - complications ; Non-alcoholic Fatty Liver Disease - epidemiology ; Non-alcoholic Fatty Liver Disease - therapy ; Nonalcoholic Fatty Liver Disease (NAFLD) ; Nonalcoholic Steatohepatitis (NASH) ; Persons With HIV (PWH)</subject><ispartof>Clinical gastroenterology and hepatology, 2022-02, Vol.20 (2), p.256-268</ispartof><rights>2022 AGA Institute</rights><rights>Copyright © 2022 AGA Institute. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c451t-b0c1313385e2ed2f6e29bfaa07261da1d62ffad514dd4a36b5b9f1778d07c9d83</citedby><cites>FETCH-LOGICAL-c451t-b0c1313385e2ed2f6e29bfaa07261da1d62ffad514dd4a36b5b9f1778d07c9d83</cites><orcidid>0000-0003-3442-4453 ; 0000-0002-0640-5514 ; 0000-0003-2882-7264 ; 0000-0001-7721-6975</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1542356520314312$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33069882$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lake, Jordan E.</creatorcontrib><creatorcontrib>Overton, Turner</creatorcontrib><creatorcontrib>Naggie, Susanna</creatorcontrib><creatorcontrib>Sulkowski, Mark</creatorcontrib><creatorcontrib>Loomba, Rohit</creatorcontrib><creatorcontrib>Kleiner, David E.</creatorcontrib><creatorcontrib>Price, Jennifer C.</creatorcontrib><creatorcontrib>Chew, Kara W.</creatorcontrib><creatorcontrib>Chung, Raymond T.</creatorcontrib><creatorcontrib>Corey, Kathleen E.</creatorcontrib><title>Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus</title><title>Clinical gastroenterology and hepatology</title><addtitle>Clin Gastroenterol Hepatol</addtitle><description>Nonalcoholic fatty liver disease (NAFLD) affects 25% of adults in the general population and is a disease spectrum ranging from steatosis to nonalcoholic steatohepatitis (NASH) to end-stage liver disease. NAFLD is an independent risk factor for cardiovascular disease, diabetes mellitus, and all-cause mortality, and NASH cirrhosis is a frequent indication for liver transplantation. In persons with human immunodeficiency virus (PWH), chronic liver disease is the second leading cause of non–human immunodeficiency virus–related mortality. Between 20% and 63% of PWH have NASH, and 14% to 63% have NASH with fibrosis. However, little is known about the optimal diagnostic strategies, risk factors for, and treatment of NAFLD in PWH. Here, we review current data on and identify knowledge gaps in the epidemiology, pathophysiology, diagnosis, and management of NAFLD in PWH and highlight priorities for research.
[Display omitted]</description><subject>Antiretroviral Therapy (ART)</subject><subject>End Stage Liver Disease - pathology</subject><subject>HIV</subject><subject>HIV Infections - complications</subject><subject>HIV Infections - epidemiology</subject><subject>HIV Infections - pathology</subject><subject>Human Immunodeficiency Virus (HIV)</subject><subject>Humans</subject><subject>Liver - pathology</subject><subject>Liver Cirrhosis - epidemiology</subject><subject>Liver Cirrhosis - pathology</subject><subject>Liver Cirrhosis - therapy</subject><subject>Non-alcoholic Fatty Liver Disease - complications</subject><subject>Non-alcoholic Fatty Liver Disease - epidemiology</subject><subject>Non-alcoholic Fatty Liver Disease - therapy</subject><subject>Nonalcoholic Fatty Liver Disease (NAFLD)</subject><subject>Nonalcoholic Steatohepatitis (NASH)</subject><subject>Persons With HIV (PWH)</subject><issn>1542-3565</issn><issn>1542-7714</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUtPGzEUha2qqEDoD-gGedlNUj_mZSFVqlIgSFFBiMfS8th3iKMZO7VnAvn3dZqA2g0rX_uee651PoS-UDKhhBbflhP9tJgwwrb3CaHVB3RE84yNy5JmH_c1z4v8EB3HuCSEiUyUn9Ah56QQVcWOkDl_WUHo8Y1y0OJbWFt4xt7hX96pVvuFb63GF6rvN3hu1xDwTxtBRcDW4RsI0buIH22_wLOhUw5fdd3gvIHGagtOb_CDDUM8QQeNaiN83p8jdH9xfjedjefXl1fTH_OxznLaj2uiKaecVzkwMKwpgIm6UYqUrKBGUVOwplEmp5kxmeJFndeioWVZGVJqYSo-Qt93vquh7sBocH1QrVwF26mwkV5Z-X_H2YV88mspUhwFJ8ng694g-N8DxF52Nmpo25SOH6JkWc6IEFzQJKU7qQ4-xgDN2xpK5JaOXMpER27pbJ8SnTRz-u__3iZecSTB2U4AKaWEIsj4N0cwNoDupfH2Hfs_QYyiJw</recordid><startdate>20220201</startdate><enddate>20220201</enddate><creator>Lake, Jordan E.</creator><creator>Overton, Turner</creator><creator>Naggie, Susanna</creator><creator>Sulkowski, Mark</creator><creator>Loomba, Rohit</creator><creator>Kleiner, David E.</creator><creator>Price, Jennifer C.</creator><creator>Chew, Kara W.</creator><creator>Chung, Raymond T.</creator><creator>Corey, Kathleen E.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-3442-4453</orcidid><orcidid>https://orcid.org/0000-0002-0640-5514</orcidid><orcidid>https://orcid.org/0000-0003-2882-7264</orcidid><orcidid>https://orcid.org/0000-0001-7721-6975</orcidid></search><sort><creationdate>20220201</creationdate><title>Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus</title><author>Lake, Jordan E. ; Overton, Turner ; Naggie, Susanna ; Sulkowski, Mark ; Loomba, Rohit ; Kleiner, David E. ; Price, Jennifer C. ; Chew, Kara W. ; Chung, Raymond T. ; Corey, Kathleen E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c451t-b0c1313385e2ed2f6e29bfaa07261da1d62ffad514dd4a36b5b9f1778d07c9d83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antiretroviral Therapy (ART)</topic><topic>End Stage Liver Disease - pathology</topic><topic>HIV</topic><topic>HIV Infections - complications</topic><topic>HIV Infections - epidemiology</topic><topic>HIV Infections - pathology</topic><topic>Human Immunodeficiency Virus (HIV)</topic><topic>Humans</topic><topic>Liver - pathology</topic><topic>Liver Cirrhosis - epidemiology</topic><topic>Liver Cirrhosis - pathology</topic><topic>Liver Cirrhosis - therapy</topic><topic>Non-alcoholic Fatty Liver Disease - complications</topic><topic>Non-alcoholic Fatty Liver Disease - epidemiology</topic><topic>Non-alcoholic Fatty Liver Disease - therapy</topic><topic>Nonalcoholic Fatty Liver Disease (NAFLD)</topic><topic>Nonalcoholic Steatohepatitis (NASH)</topic><topic>Persons With HIV (PWH)</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lake, Jordan E.</creatorcontrib><creatorcontrib>Overton, Turner</creatorcontrib><creatorcontrib>Naggie, Susanna</creatorcontrib><creatorcontrib>Sulkowski, Mark</creatorcontrib><creatorcontrib>Loomba, Rohit</creatorcontrib><creatorcontrib>Kleiner, David E.</creatorcontrib><creatorcontrib>Price, Jennifer C.</creatorcontrib><creatorcontrib>Chew, Kara W.</creatorcontrib><creatorcontrib>Chung, Raymond T.</creatorcontrib><creatorcontrib>Corey, Kathleen E.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical gastroenterology and hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lake, Jordan E.</au><au>Overton, Turner</au><au>Naggie, Susanna</au><au>Sulkowski, Mark</au><au>Loomba, Rohit</au><au>Kleiner, David E.</au><au>Price, Jennifer C.</au><au>Chew, Kara W.</au><au>Chung, Raymond T.</au><au>Corey, Kathleen E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus</atitle><jtitle>Clinical gastroenterology and hepatology</jtitle><addtitle>Clin Gastroenterol Hepatol</addtitle><date>2022-02-01</date><risdate>2022</risdate><volume>20</volume><issue>2</issue><spage>256</spage><epage>268</epage><pages>256-268</pages><issn>1542-3565</issn><eissn>1542-7714</eissn><abstract>Nonalcoholic fatty liver disease (NAFLD) affects 25% of adults in the general population and is a disease spectrum ranging from steatosis to nonalcoholic steatohepatitis (NASH) to end-stage liver disease. NAFLD is an independent risk factor for cardiovascular disease, diabetes mellitus, and all-cause mortality, and NASH cirrhosis is a frequent indication for liver transplantation. In persons with human immunodeficiency virus (PWH), chronic liver disease is the second leading cause of non–human immunodeficiency virus–related mortality. Between 20% and 63% of PWH have NASH, and 14% to 63% have NASH with fibrosis. However, little is known about the optimal diagnostic strategies, risk factors for, and treatment of NAFLD in PWH. Here, we review current data on and identify knowledge gaps in the epidemiology, pathophysiology, diagnosis, and management of NAFLD in PWH and highlight priorities for research.
[Display omitted]</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>33069882</pmid><doi>10.1016/j.cgh.2020.10.018</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0003-3442-4453</orcidid><orcidid>https://orcid.org/0000-0002-0640-5514</orcidid><orcidid>https://orcid.org/0000-0003-2882-7264</orcidid><orcidid>https://orcid.org/0000-0001-7721-6975</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1542-3565 |
| ispartof | Clinical gastroenterology and hepatology, 2022-02, Vol.20 (2), p.256-268 |
| issn | 1542-3565 1542-7714 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9069630 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Antiretroviral Therapy (ART) End Stage Liver Disease - pathology HIV HIV Infections - complications HIV Infections - epidemiology HIV Infections - pathology Human Immunodeficiency Virus (HIV) Humans Liver - pathology Liver Cirrhosis - epidemiology Liver Cirrhosis - pathology Liver Cirrhosis - therapy Non-alcoholic Fatty Liver Disease - complications Non-alcoholic Fatty Liver Disease - epidemiology Non-alcoholic Fatty Liver Disease - therapy Nonalcoholic Fatty Liver Disease (NAFLD) Nonalcoholic Steatohepatitis (NASH) Persons With HIV (PWH) |
| title | Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T13%3A32%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Expert%20Panel%20Review%20on%20Nonalcoholic%20Fatty%20Liver%20Disease%20in%20Persons%20With%20Human%20Immunodeficiency%20Virus&rft.jtitle=Clinical%20gastroenterology%20and%20hepatology&rft.au=Lake,%20Jordan%20E.&rft.date=2022-02-01&rft.volume=20&rft.issue=2&rft.spage=256&rft.epage=268&rft.pages=256-268&rft.issn=1542-3565&rft.eissn=1542-7714&rft_id=info:doi/10.1016/j.cgh.2020.10.018&rft_dat=%3Cproquest_pubme%3E2452099391%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2452099391&rft_id=info:pmid/33069882&rft_els_id=S1542356520314312&rfr_iscdi=true |